Intravascular large B-cell lymphoma (IVLBCL) is a rare type of non-Hodgkin’s lymphoma. Its symptoms can vary, making it difficult to diagnose. The outlook for people with IVLBCL is typically poor.

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

Diffuse large B-cell lymphoma is a common type of fast-growing (high-grade) non-Hodgkin lymphoma (NHL), responsible for about 40% of NHL cases in adults. Around 4300 people are diagnosed each year ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who ... representing 25% of all lymphoma cases. An additional 40% have relapsed or ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...